Sanofi Stays Bullish On Synthorx IL-2 Drug, But It’s Early Days

Drug Maker Presents Initial Phase I Data At AACR

 
• By Alaric DeArment
  
Cancer
Sanofi presented early data at AACR on THOR-707, the IL-2 drug it acquired when it bought Synthorx in 2019. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category